Reverse Vaccinology: Developing Vaccines in the Era of Genomics

Slides:



Advertisements
Similar presentations
Maintaining Cell Identity through Global Control of Genomic Organization Gioacchino Natoli Immunity Volume 33, Issue 1, Pages (July 2010) DOI: /j.immuni
Advertisements

The Transcription Factor Foxo1 Controls Central-Memory CD8+ T Cell Responses to Infection Myoungjoo V. Kim, Weiming Ouyang, Will Liao, Michael Q. Zhang,
Human Epidermal Langerhans Cells Maintain Immune Homeostasis in Skin by Activating Skin Resident Regulatory T Cells Julien Seneschal, Rachael A. Clark,
IPSC Crowdsourcing: A Model for Obtaining Large Panels of Stem Cell Lines for Screening Mahendra Rao Cell Stem Cell Volume 13, Issue 4, Pages (October.
Lung Airway-Surveilling CXCR3hi Memory CD8+ T Cells Are Critical for Protection against Influenza A Virus Bram Slütter, Lecia L. Pewe, Susan M. Kaech,
$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.
E-Clinical
Vaccines for the elderly
Septic Shock: On the Importance of Being Tolerant
Predicting Vaccine Responsiveness
Volume 31, Issue 2, Pages (August 2009)
Of Worms and Men: HLH-30 and TFEB Regulate Tolerance to Infection
? Neutralizing Antibodies: Research pathways in 2013 and beyond
Central Dogma Goes Digital
Trained Immunity: An Ancient Way of Remembering
HIV-1 Latency by Transition
Systems Vaccinology Immunity
An Activation Marker Finds a Function
Making It Personal: Neoantigen Vaccines in Metastatic Melanoma
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease
Joseph C. Mudd, Jason M. Brenchley  Immunity 
Vaccine Adjuvants: Putting Innate Immunity to Work
From Oncogene Interference to Neutrophil Immune Modulation
New Hope in the Search for Ebola Virus Treatments
Toll-like Receptors Keep Antigen Sorting on the Right Track
Treg's Alter Ego: An Accessory in Tumor Killing
Chronic Infections Capture Little Attention of the Masses
Communication in Drug Development: “Translating” Scientific Discovery
A Flt3L Encounter: mTOR Signaling in Dendritic Cells
Redefining Clinical Trials: The Age of Personalized Medicine
T Helper 17 Cells Get the NOD
Volume 25, Issue 10, Pages (October 2017)
Unraveling the Pros and Cons of Interferon-γ Gene Regulation
Mitchell Kronenberg, Yuki Kinjo  Immunity 
PU.1 Takes Control of the Dendritic Cell Lineage
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
Foxo1 and Foxo3 help Foxp3 Immunity
How To Choose a Good Scientific Problem
Thymic Selection: To Thine Own Self Be True
Jan Philipp Junker, Alexander van Oudenaarden  Molecular Cell 
Shannon M. Kahan, Allan J. Zajac  Immunity 
Interleukin-17 Kick-Starts T Helper 1 Cell Differentiation
Chronic Infections Capture Little Attention of the Masses
Training for the infectious diseases speciality in Norway
Zika Virus: Immunity and Vaccine Development
MicroRNAs and Viral Infection
Volume 21, Issue 9, Pages (September 2014)
A.P. Underwood, J. Green  Clinical Microbiology and Infection 
From Vanilla to 28 Flavors: Multiple Varieties of T Regulatory Cells
Vaccines for the elderly
Modeling Rett Syndrome with Stem Cells
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease
Clinical Translation of Stem Cell Therapies: A Bridgeable Gap
Immunologic Basis of Vaccine Vectors
IL-22 from T Cells: Better Late than Never
A FIRE-y PAGE in the Computational Analysis of Cancer Profiles
The Plasticity of Aging: Insights from Long-Lived Mutants
Eystein S. Husebye, Mark S. Anderson  Immunity 
Eystein S. Husebye, Mark S. Anderson  Immunity 
Taking a Toll Road to Better Vaccines
Recycling Endosomes and TLR Signaling— The Rab11 GTPase Leads the Way
How To Choose a Good Scientific Problem
Regulatory T Cells GATA Have It
t Testing the Immune System
From Vaccines to Memory and Back
PTENtiating CFTR for Antimicrobial Immunity
Volume 12, Issue 6, Pages (December 2007)
A “Big Data” View of the Tumor “Immunome”
IL-9 by INFERence Immunity
CTLA4Ig: Bridging the Basic Immunology with Clinical Application
Presentation transcript:

Reverse Vaccinology: Developing Vaccines in the Era of Genomics Alessandro Sette, Rino Rappuoli  Immunity  Volume 33, Issue 4, Pages 530-541 (October 2010) DOI: 10.1016/j.immuni.2010.09.017 Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 1 Schematic Diagram Summarizing the Pathway of Vaccine Development Starting from Reverse Vaccinology (1) First, computer analysis of the whole genome identifies the genes coding for predicted antigens and eliminates antigens with homologies to human proteins. (2) Then the identified antigens are screened for expression by the pathogen and for immunogenicity during infection. (3) The selected antigens are then used to immunize animals and test whether immunization induces a protective response. (4) Protective antigens are then tested for their presence and conservation in a collection of strains representative of the species (molecular epidemiology). (5) Finally, selected antigens are manufactured in large scale for clinical trials, and candidate vaccines are tested for safety and protective immunity in humans using established correlates of protection or efficacy studies. (6) Scientific, clinical, and technical information is then analyzed and approved by regulatory agencies, such as the Food and Drug Administration (FDA) or the European Medicinal Agency (EMA). (7) Policy-making bodies, such as the ACIP and equivalent bodies from other nations, make the recommendation on how the vaccine should be used. (8) The approved vaccine is then commercialized and used in large scale. At this point, phase IV clinical studies confirm safety. Immunity 2010 33, 530-541DOI: (10.1016/j.immuni.2010.09.017) Copyright © 2010 Elsevier Inc. Terms and Conditions